Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
Palvella Therapeutics presented new Phase 2 data from the TOIVA trial of QTORIN rapamycin for cutaneous venous malformations at the Society for Investigative Dermatology meeting. The data showed that 100% of patients with bleeding at baseline (n=4) achieved statistically significant improvement in bleeding scores (+2.5 points, p=0.003) and reported being satisfied or very satisfied with the treatment at Week 12.
Key figures
- Drug Name
- QTORIN rapamycin
- Phase Of Trial
- Phase 2
- Bleeding p value
- 0.003
- Satisfaction rate
- 100%
- Us patient population
- 75,000
- Patients with bleeding
- 4
- Bleeding improvement score
- +2.5
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.